This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
5 Small-Cap Sector ETFs Leading the Russell 2000 Rally
by Sweta Killa
We have presented five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
5 Small-Cap ETFs at the Forefront of the 2021 Market Rally
by Sweta Killa
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
5 Small-Cap Sector ETFs Beating the Russell 2000
by Sweta Killa
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.